	US 12,404,490 B2
	AGGF1 immunogenic compositions
Stephen Charles Benz, Culver City, CA (US); Andrew Nguyen, Culver City, CA (US); Charles Joseph Vaske, Culver City, CA (US); and John Zachary Sanborn, Culver City, CA (US)
Assigned to NantOmics LLC, Culver City, CA (US)
Filed by Nantomics LLC, Culver City, CA (US)
Filed on Oct. 5, 2022, as Appl. No. 17/938,270.
Application 17/938,270 is a continuation of application No. 16/571,008, filed on Sep. 13, 2019, granted, now 11,504,420.
Application 16/571,008 is a continuation of application No. 15/565,203, abandoned, previously published as PCT/US2016/026798, filed on Apr. 8, 2016.
Claims priority of provisional application 62/144,745, filed on Apr. 8, 2015.
Prior Publication US 2023/0210969 A1, Jul. 6, 2023
Int. Cl. A61K 47/68 (2017.01); A61K 39/00 (2006.01); C07K 14/47 (2006.01); C07K 16/22 (2006.01); C07K 16/30 (2006.01); C12N 5/0783 (2010.01); C12N 5/09 (2010.01); G01N 33/574 (2006.01)

CPC C12N 5/0638 (2013.01) [A61K 39/001102 (2018.08); A61K 39/001144 (2018.08); A61K 47/6851 (2017.08); C07K 14/4702 (2013.01); C07K 16/22 (2013.01); C07K 16/30 (2013.01); C12N 5/0646 (2013.01); C12N 5/0693 (2013.01); G01N 33/57407 (2013.01); A61K 2039/505 (2013.01); A61K 2039/53 (2013.01); A61K 2039/80 (2018.08); A61K 2039/812 (2018.08); A61K 2039/892 (2018.08); C07K 2317/34 (2013.01); C07K 2319/55 (2013.01); C07K 2319/60 (2013.01)]

14 Claims

1. A method of producing an antibody and directing the antibody to a cancer cell expressing a neoepitope in human angiogenic factor with G patch and FHA domains 1 (AGGF1) protein, the method comprising:

producing an antibody by immunizing a mammal with a peptide consisting of SEQ ID NO: 1, SEQ ID NO:2, or SEQ ID NO:3, and isolating an antibody that binds to the peptide consisting of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3; and

contacting a cancer cell with the isolated antibody, wherein the neoepitope in the human AGGF1 protein comprises a V202L mutation.